Curative Effect Analysis Of Ranibizumab Combine With Pars Plana Vitrectomy For The Treatment Of Proliferative Diabetic Retinopathy

Objective:This study was designed to investigate the efficacy of intravitreal injection of ranibizumab in the treatment of PDR before pars plana vitrectomy.Methods:retrospective analysis of the data of 59 patients(71 eyes)with pars plana vitrectomy from January 2013 to June 2017 in the Department of Ophthalmology of Second affiliated Hospital of Jilin University.Statistical analysis of their clinical data.According to whether or not intravitreal injection of ranibizumab before pars plana vitrectomy was divided intotwo groups: pars plana vitrectomy(PPV)group:29 cases(35 eyes);intravitreal injection of ranibizumab before pars plana vitrectomy vitrectomy(IVR/PPV)group:30 cases(36 eyes).To analysis there surgical time,intraoperative complications(iatrogenicretinal breaks,intraoperative hemorrhage),types of tamponade,visual acuity at postoperative,intraocular pressure of postoperative,and the rehemorrhage of postoperative.Results:1.The average surgical time of IVR/PPV group(93.03±29.71 minutes)was significantly shorter than PPV group(116.25±29.71 minutes),the difference was statistically significant(P=0.001).2.The incidence of intraoperative hemorrhage and iatrogenic retinal breaks was significantly reduced in IVR/PPV group,the difference was statistically significant(P=0.019;P=0.022).3.The rate of silicone oil tamponade in the IVR/PPV group(66.67%)was lower than that in the PPV group(88.57 %),the difference was statistically significant(P = 0.027).4.The incidence of intraocular pressure of postoperative and the rehemorrhage of postoperative inIVR/PPV group was lower than in PPV group,the difference was statistically significant(P = 0.014,P = 0.019).5.Three months after the operation,the visual acuity of both groups was improved compared with the preoperative level.The visual acuity of the IVR/PPV group was better than the PPV group.The difference was not statistically significant(P=0.089).Conclusion:1.Intravitreal injection of ranibizumab before pars plana vitrectomy can shorten the surgery time in patients with PDR.2.Intravitreal injection of ranibizumab before pars plana vitrectomy can reduce intraoperative complications of surgery in patients with PDR(iatrogenic retinal breaks,intraoperative hemorrhage).3.Intravitreal injection of ranibizumab before pars plana vitrectomy can reduce the silicone oil tamponade rate in patients with PDR.4.Intravitreal injection of ranibizumab before pars plana vitrectomy can reduce the incidence of early postoperative complications(re-vitreous hemorrhage and postoperative intraocular hypertension)in patients with PDR.5.Intravitreal injection of ranibizumab before pars plana vitrectomy has no effect on the postoperative visual acuity of PDR patients.